Jiangsu Hualan Stock Hits Day High Amid Strong Intraday Performance

Jiangsu Hualan New Pharmaceutical Material Co., a large-cap player in the packaging industry, has seen a notable increase of 4.85% on June 16, 2026, reaching an intraday high of CNY 132.16. Despite this upward movement, the company faces significant challenges reflected in its financial metrics. The Return on Capital Employed (ROCE) stands at a low 9.64%, indicating limited profitability relative to the capital utilized. Over the past five years, the company has experienced a decline in net sales, averaging an annual decrease of 5.82%, while operating profit has plummeted by 40.66%. This trend is further underscored by a reported 11% drop in net sales, leading to negative results for seven consecutive quarters. Additionally, the company’s Return on Equity (ROE) is at a modest 1.59%, with a high Price to Book ratio of 8.78, suggesting an expensive valuation. Despite a remarkable return of 308.54% over the past year, profits have decreased by 30.7%. The current dividend yield remains low at 0.03%, reflecting the company's ongoing financial difficulties.